Hans-Ulrich Demuth
Geen lopende functies
Profiel
Hans-Ulrich Demuth was the founder of Vivoryon Therapeutics NV, which was founded in 1997, where he held the title of Chief Scientific Officer from 2009 to 2013.
He was also a Co-Managing Director at Ingenium Pharmaceuticals GmbH in 2012.
In addition, he was a Principal at Hochschule Anhalt and a Mitglied at Martin-Luther-Universität Halle-Wittenberg.
Dr. Demuth received his undergraduate degree from Martin-Luther-Universität Halle-Wittenberg.
Eerdere bekende functies van Hans-Ulrich Demuth
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Oprichter | 31-01-2013 |
| Hochschule Anhalt | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Algemeen Directeur | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
Opleiding van Hans-Ulrich Demuth
| Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |